We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Wearable Defibrillator Protects Patients from Cardiac Arrest

By HospiMedica International staff writers
Posted on 30 Mar 2017
A portable defibrillator continuously protects patients at risk from ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes during their stay in the hospital.

The ZOLL Hospital Wearable Defibrillator (HWD) provides patients at risk for VT or VF with continuous protection anytime (day or night) in the hospital through automatic detection and immediate, timely defibrillation within 60 seconds. The device continuously monitors the patient's heart using dry, non-adhesive sensing electrodes to detect abnormal heart rhythms. If such a life-threatening cardiac rhythm is detected, the device alerts the patient prior to delivering a treatment shock, allowing a conscious patient to delay the shock.

Image: The Hospital Wearable Defibrillator protects patients at risk of VT or VF (Photo courtesy of ZOLL).
Image: The Hospital Wearable Defibrillator protects patients at risk of VT or VF (Photo courtesy of ZOLL).

The HWD identifies life-threatening VT/VF using the same arrhythmia detection algorithm used in the LifeVest wearable defibrillator for outpatients, which analyzes both heart rate and QRS morphology, making it highly sensitive and specific to treatment of ventricular arrhythmias, resulting in exclusion of rhythms that are neither VT or VF. The ZOLL HWD is product of ZOLL Medical Corporation, and has been approved by the U.S. Food and Drug Administration (FDA).

“The HWD offers hospital care teams a new option for managing patients at risk of VT/VF by providing continuous protection even outside of very expensive, high-acuity care areas,” said Jonathan Rennert, CEO of ZOLL. “It complements the tool kit the care team has in place for responding to cardiac arrest.”

“The ability to provide hospitalized patients at risk for malignant ventricular arrhythmias a safe and effective device that enables rapid defibrillation represents a significant improvement in the care of cardiovascular patients,” said David Shavelle, MD, of the University of Southern California (USC; Los Angeles, USA).

VF and VT are life-threatening abnormal heart rhythms that are the most common cause of sudden cardiac arrest (SCA), according to the U.S. National Heart, Lung and Blood Institute. Diseases and conditions that can lead to SCA include heart disease and inherited disorders and structural changes in the heart, such as those resulting from congenital heart disease (CHD) or infection. Most people who suffer SCA will die from it, often within minutes. Rapid treatment with a defibrillator can save their lives.


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Pre-Op Planning Solution
Sectra 3D Trauma

Latest Critical Care News

First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD

AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases

Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time